Compare Goldman Sachs Group Inc (GS) vs TransMedics Group Inc (TMDX) Price & Performance

Goldman Sachs (GS) trades at $882.59, down 0.52% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company shows strong profitability with a 31.68% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights CEO David Solomon's focus on expanding earnings and building a durable revenue base, while the FICC business is expected to soften in Q3 2026.

The stock presents a mixed outlook: attractive valuation with a P/E of 13.63 and consensus price target of $1,130 suggests upside, but negative operating cash flows and high debt levels pose risks. Analyst sentiment is cautious with 40% buy ratings, while institutional interest remains steady. Key catalysts include revenue growth in asset and wealth management, but macroeconomic volatility and competitive pressures could hinder performance.

TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.

The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.